Education
About Us
Working with TipRanks
Follow Us
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
UNCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.20 - $1.60
Previous CloseN/A
Volume1.16M
Average Volume (3M)853.64K
Market Cap
$59.67M
Enterprise Value$65.04M
Total Cash (Recent Filing)$24.33M
Total Debt (Recent Filing)$991.00K
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 20, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding103,796,410
10 Day Avg. Volume978,588
30 Day Avg. Volume853,645
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)114.16
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit96.36
Enterprise Value/Ebitda-1.64
Forecast
1Y Price Target
$7.25Price Target Upside1171.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityUnicycive expects its cash reserves to provide financial stability until 2026, which is favorable for long-term planning.
Product Launch StrategyManagement is actively preparing for the product launch by recruiting a small, targeted salesforce and designing a reimbursement hub, indicating a strategic focus on market penetration.
Regulatory ApprovalThe PDUFA date for the NDA of lead asset oxylanthanum carbonate for treatment of hyperphosphatemia in chronic kidney disease patients is anticipated to lead to significant stock appreciation upon likely approval.
Bears Say
Commercialization RisksRisks also include failure to secure a commercialization partner or sufficient capital to market products independently.
Market CompetitionA smaller than anticipated commercial opportunity due to market size, competition, and pricing is a potential risk to the target price.
Regulatory RisksRisks include failure to secure regulatory approvals for OLC or UNI-494.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UNCY FAQ
What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $0.20 and its highest was $1.60 in the past 12 months.
What is Unicycive Therapeutics’s market cap?
Unicycive Therapeutics’s market cap is $59.67M.
When is Unicycive Therapeutics’s upcoming earnings report date?
Unicycive Therapeutics’s upcoming earnings report date is May 20, 2025 which is in 48 days.
How were Unicycive Therapeutics’s earnings last quarter?
Unicycive Therapeutics released its earnings results on Mar 31, 2025. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of -$0.017 by $0.267.
Is Unicycive Therapeutics overvalued?
According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued.
Does Unicycive Therapeutics pay dividends?
Unicycive Therapeutics does not currently pay dividends.
What is Unicycive Therapeutics’s EPS estimate?
Unicycive Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Unicycive Therapeutics have?
Unicycive Therapeutics has 103,796,410 shares outstanding.
What happened to Unicycive Therapeutics’s price movement after its last earnings report?
Unicycive Therapeutics reported an EPS of $0.25 in its last earnings report, beating expectations of -$0.017. Following the earnings report the stock price went down -6.557%.
Which hedge fund is a major shareholder of Unicycive Therapeutics?
Among the largest hedge funds holding Unicycive Therapeutics’s share is RA Capital Management. It holds Unicycive Therapeutics’s shares valued at 0.
---
Unicycive Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.25 (1171.93% Upside)
$7.25 (1171.93% Upside)
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-61.27%
12-Months-Change
Fundamentals
Return on Equity
-2355.27%
Trailing 12-Months
Asset Growth
123.16%
Trailing 12-Months
Company Description
Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
---
UNCY Stock 12 Month Forecast
Average Price Target
$7.25
▲(1171.93% Upside)
Technical Analysis
Alkermes
―
BioCryst
―
Corbus Pharmaceuticals
―
Akari Therapeutics
―
Atea Pharmaceuticals
―
Best Analysts Covering UNCY
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+1.26%
reiterated a buy rating 2 days ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.26% per trade.
---